Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
about
Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and preventionProstate MRI based on PI-RADS version 2: how we review and reportUrinary biomarkers for prostate cancerActive surveillance for prostate cancer: current evidence and contemporary state of practiceProstate cancer screening with prostate-specific antigen: A guide to the guidelinesProstate cancer in Brazil and Latin America: epidemiology and screeningElevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohortNon-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening TrialFocal therapy as primary treatment for localized prostate cancer: definition, needs and future.Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Prognostic Significance and Functional Role of CEP57 in Prostate CancerQuantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.Patterns of care and treatment trends for Canadian men with localized low-risk prostate cancer: an analysis of provincial cancer registry dataProstate-specific antigen testing rates and referral patterns from general practice data in England.Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App.Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.Characteristics of prostate cancer detection rate (PCDR) in Chinese Han population under different prostate biopsy methods.The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era.Recommendations on screening for prostate cancer with the prostate-specific antigen test.The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.Serum markers in prostate cancer detectionHighlights of the university of toronto urology update 2014.Prostate-specific antigen-based screening: controversy and guidelinesThe feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria.Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases.Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection ProgramLifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010Ethnicity and prostate cancer: the way to solve the screening problem?Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia.Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review.Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.Epigenetically altered miR-193b targets cyclin D1 in prostate cancerA positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary prostate biopsyCD147 and Prostate Cancer: A Systematic Review and Meta-Analysis.An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?
P2860
Q26742027-5AB73414-01C5-4831-BD8D-34D69F211AF6Q26749289-8B3FABEC-66CF-46F0-AE79-E5B706161604Q27009110-2A63512B-6E5F-4B1E-9F50-1F5304F41D4DQ28066534-F3932F42-11FC-4C87-BE74-D7530C37391BQ28070347-25CD25CF-1DD7-4918-B7AC-493EE0FF389CQ28079012-EDD0A001-F99A-4BEB-BE18-F9B6ADFED042Q28546311-392EF2A0-28C0-47F5-B0E8-FACA9A65C3C1Q28551492-A9ABE6B0-028F-46BA-96C7-82122358917FQ30240753-6812B50E-5D10-41CF-8BBF-0BAD25E44C20Q30354652-66FADCE6-5CAB-49AE-8B4F-CB01BACAF68EQ30361019-D585A887-1D4D-4EBD-8884-A6FF810A0229Q30395328-0D2BBAFF-D84C-47AC-8234-D3279A32F11CQ30878080-AF38E248-75C2-4A19-A611-F5C167FD5FE7Q31056768-5D2BD752-4C0D-45A1-8C9E-C7E5F283425CQ31059950-FF86A939-FF4E-412A-8D7F-8E917C0AC4B4Q33454007-7BA8E513-96AD-465D-B1BF-D2EF779CC680Q33676037-94E88BE6-CBE7-4ECE-88E5-B65DE68ADEC1Q33779314-DC5A0D84-9271-4531-90FF-6FA58DED2BB6Q34042937-1F1CBD11-5440-49FD-B096-9B93C6A6A375Q34435885-C13FC1AB-F456-4C25-8E1B-82B07205C0A8Q34512629-39358ACA-5304-43C0-B1C6-917FEBA36760Q35042519-6A8B4199-2079-4AD9-A5CE-C996E4A51EECQ35100023-C9C0493B-321C-4D0D-B214-39AAA3985EE4Q35211931-EBE51B0D-6B75-4495-A3CC-752EF4DE864AQ35568883-74B7DEF8-BA8C-4837-99C6-04061213CB10Q35602297-E268D10C-DA1A-4534-8BD1-6FD058B044ACQ35675628-F47F5A07-9E06-4C2C-9F32-59523D0287C8Q35720012-B74449D7-3FCC-47E6-B9C0-DE4D3A75B9F4Q35724984-3F5CA36C-B2A7-4BFC-B922-AC79A732367FQ35736485-E98C1982-DA5E-4431-8DA9-22853F3A3BCBQ35832798-9388EEF7-E711-4652-93EA-441719806170Q35881136-B47A04FB-DB44-488D-904F-7290B4E43A87Q35944835-6130FB56-B48F-4AE8-A62D-CC174E625A90Q35992097-25FF0E06-80A8-4A66-8D7A-D1EF3E109115Q36009824-08EB1841-CFEC-48FA-8EF9-737AF3F99F0EQ36051375-42AD3251-9D1E-423F-9384-6977606509C2Q36051801-96CAFBEC-DCCB-4CEC-88F9-9988AD14F9ECQ36071104-787ACC97-81B7-481D-9ECA-25B8DF3133E9Q36148171-F86C7FB5-51A1-4A77-8DC0-8C8FBE688E6BQ36199134-DB1957AB-6367-456D-93F1-0AF6CECD6C96
P2860
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Screening and prostate cancer ...... SPC) at 13 years of follow-up.
@ast
Screening and prostate cancer ...... SPC) at 13 years of follow-up.
@en
Screening and prostate cancer ...... Screening for Prostate Cancer
@nl
type
label
Screening and prostate cancer ...... SPC) at 13 years of follow-up.
@ast
Screening and prostate cancer ...... SPC) at 13 years of follow-up.
@en
Screening and prostate cancer ...... Screening for Prostate Cancer
@nl
prefLabel
Screening and prostate cancer ...... SPC) at 13 years of follow-up.
@ast
Screening and prostate cancer ...... SPC) at 13 years of follow-up.
@en
Screening and prostate cancer ...... Screening for Prostate Cancer
@nl
P2093
P2860
P50
P1433
P1476
Screening and prostate cancer ...... RSPC) at 13 years of follow-up
@en
P2093
Alvaro Paez
Andreas Huber
Chris H Bangma
ERSPC Investigators
Franz Recker
Fritz H Schröder
Gunnar Aus
Hans Lilja
Harry J de Koning
Jonas Hugosson
P2860
P304
P356
10.1016/S0140-6736(14)60525-0
P407
P577
2014-08-06T00:00:00Z